Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Medicines Co.’s Cangrelor’s Full CHAMPION PHOENIX Results Bode Well For Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

After two failed studies, The Medicines Co.’s rapid-acting IV antiplatelet drug reduces events by more than 20% in the Phase III CHAMPION PHOENIX angioplasty trial against Plavix. However, the company is already facing demand for studies against the newer and more potent antiplatelet drugs Brilinta and Effient.

You may also be interested in...

Cangrelor’s Approval Prospects: FDA Reviewers Say Yes, Team Leader Says No

As The Medicines Co.’s anticlotting drug heads to the Cardiovascular and Renal Drugs Advisory Committee, questions about comparator dosing and timing and the severity of bleeding events will be on the agenda.

The Medicines Co.’s Cangrelor Rises From The Ashes Of Phase III

TMC reported successful top-line data from its Phase III PHOENIX study of its anticlotting drug cangrelor and expects to file an NDA this year.

Is TMS' Cangrelor A CHAMPION After All? "Noise On The Line" Confounded Endpoint Data, CEO Says

Speeding heart attack patients into the PCI lab may have blurred the timeline on their MIs and botched endpoint data, says Meanwell.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts